Skip to main content

Advertisement

SpringerLink
Log in

Analysis of cytogenetic aberrations in sporadic vestibular schwannoma by comparative genomic hybridization

  • Laboratory Investigation - Human/Animal Tissue
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Vestibular schwannomas (VS) are benign tumors of the nervous system that are usually sporadic but also occur in the inherited disorder neurofibromatosis type 2 (NF2). The NF2 gene is a tumor suppressor gene located on chromosome 22. Loss of the NF2 protein product, Merlin, is universal in both sporadic and NF2-related schwannomas and the loss or mutation of the gene is the only established causative event underlying schwannoma formation. Comparative genomic hybridization (CGH) was used to screen 20 sporadic VS to identify additional chromosomal regions that may harbor genes involved in VS-tumorigenesis. The most common change were losses on chromosome 22q. Additionally, losses were observed on chromosome 9p indicating a possible participation of the CDKN2A tumor suppressor gene in the genesis of VS. Gains were observed on 17q, 19p and 19q, which have been reported before in malignant peripheral nerve sheath tumors that are associated with neurofibromatosis type 1. Importantly, high level amplifications have been observed on 16p and 16q as well as on 9q, suggesting the possible involvement of several oncogenes in the tumorigenesis of VS. Our data suggest the involvement of various oncogenes and tumor suppressor genes might play a role in the genesis of the vestibular schwannomas apart from the inactivation of the NF2 gene.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Abbreviations

CGH:

Comparative genomic hybridization

VS:

Vestibular schwannoma

NF:

Neurofibromatosis

References

  1. Charabi S, Tos M, Thomsen J, Charabi B, Mantoni M (2000) Vestibular schwannoma growth: the continuing controversy. Laryngoscope 110:1720–1725

    Article  PubMed  CAS  Google Scholar 

  2. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, NewtonV Strachan T, Ramsden R, Harris R (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841–846

    Article  PubMed  CAS  Google Scholar 

  3. Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Maher ER (1994) Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma. Hum Mol Genet 3:347–350

    Article  PubMed  CAS  Google Scholar 

  4. Telenius H, Carter NP, Bebb CE, Nordenskjold M, Ponder BA, Tunnacliffe A (1992) Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics 13:718–725

    Article  PubMed  CAS  Google Scholar 

  5. Kalliomeni A, Kalliomeni OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D (1994) Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10:231–243

    Article  Google Scholar 

  6. du Manoir S, Speicher MR, Joos S, Schrock E, Popp S, Dohner H, Kovacs G, Robert-Nicoud M, Lichter P, Cremer T (1993) Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet 90:590–610

    PubMed  CAS  Google Scholar 

  7. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Xuan-K Hoang, Demczuk S, Desmaze Z, Plougastel B (1993) Alteration in a new gene encoding a putative membrane-organizing causes neuro-fibromatosis type 2. Nature 363:515–521

    Article  PubMed  CAS  Google Scholar 

  8. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K (1993) A novel moezin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor supressor gene. Cell 72:791–800

    Article  PubMed  CAS  Google Scholar 

  9. Warren C, James LA, Ramsden RT, Wallace A, Baser ME, Varley JM, Evans DG (2003) Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridization. J Med Genet 40:802–806

    Article  PubMed  CAS  Google Scholar 

  10. Ikeda T, Hashimoto S, Fukushige S, Ohmori H, Horii A (2005) Comparative genomic hybridization and mutation analyses of sporadic schwannomas. J Neurooncol 72:225–230

    Article  PubMed  CAS  Google Scholar 

  11. Antinheimo J, Sallinen SL, Sallinen P, Haapasalo H, Helin H, Horelli-Kuitunen N, Wessman M, Sainio M, Jääskeläinen J, Carpén O (2000) Genetic aberrations in sporadic and neurofibromatosis 2 (NF2)-associated schwannomas studied by comparative genomic hybridization (CGH). Acta Neurochir 142:1099–1104

    Article  CAS  Google Scholar 

  12. Serano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707

    Article  Google Scholar 

  13. Merlo GR, Cropp CS, Callahan R, Takahashi T (1991) Detection of loss of heterozygosity in tumor DNA samples by PCR. Biotechniques 11:166–171

    PubMed  CAS  Google Scholar 

  14. Berner JM, Sørlie T, Mertens F, Henriksen J, Saeter G, Mandahl N, Brøgger A, Myklebost O, Lothe RA (1999) Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB pathway. Genes Chromosomes Cancer 26:151–160

    Article  PubMed  CAS  Google Scholar 

  15. Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, Han ZY, Chareyre F, Niwa-Kawakita M, Black PM, Carroll RS, Giovannini M (2008) Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol 18:62–70

    Article  PubMed  Google Scholar 

  16. Rylova SN, Amalfitano A, Persaud-Sawin DA, Guo WX, Chang J, Jansen PJ, Proia AD, Boustany RM (2002) The CLN3 gene is a novel molecular target for cancer drug discovery. Cancer Res 62:801–808

    PubMed  CAS  Google Scholar 

  17. Scoles DR, Yong WH, Qin Y, Wawrowsky K, Pulst SM (2006) Schwannomin inhibits tumorigenesis through direct interaction with the eucaryotic initiation factor subunit c (elF3c). Hum Mol Genet 15:1059–1070

    Article  PubMed  CAS  Google Scholar 

  18. Richards FM, McKee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA, McKeown C, Sanders DS, Maher ER (1999) Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 8:607–610

    Article  PubMed  CAS  Google Scholar 

  19. Silye R, Karayiannakis AJ, Syrigos KN, Poole S, van Noorden S, Batchelor W, Regele H, Sega W, Boesmueller H, Krausz T, Pignatelli M (1998) E-cadherin/catenin complex in benign and malignant melanocytic lesions. J Pathol 186:350–355

    Article  PubMed  CAS  Google Scholar 

  20. Hasegawa M, Muramatsu N, Tohma Y, Fukaya K, Fujisawa H, Hayashi Y, Tachibana O, Kida S, Yamashita J, Saito K (2002) Expression of E-cadherin–catenin complex in human benign schwannomas. Histol Histopathol 17:39–44

    PubMed  CAS  Google Scholar 

  21. Schmidt H, Taubert H, Würl P, Bache M, Bartel F, Holzhausen HJ, Hinze R (2001) Cytogenetic characterization of six malignant peripheral nerve sheath tumors: comparison of karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 128:14–23

    Article  PubMed  CAS  Google Scholar 

  22. Woltuis RM, Bos JL (1999) Ras caught in another affair: the exchange factors for Ral. Curr Opin Genet Dev 9:112–117

    Article  Google Scholar 

  23. González-García A, Pritchard CA, Paterson HF, Mavria G, Stamp G, Marshall CJ (2005) RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell 7:219–226

    Article  PubMed  Google Scholar 

  24. Gill S, Stratton MR, Patterson H, Spurr NK, Fisher C, Gusterson BA, Cooper CS (1991) Detection of transforming genes by transfection of DNA from primary soft-tissue tumors. Oncogene 6:1651–1656

    PubMed  CAS  Google Scholar 

  25. Bustelo XR (2000) Regulatory and signaling properties of the Vav family. Mol Cell Biol 20:1461–1477

    Article  PubMed  CAS  Google Scholar 

  26. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, Bommert K, Mechta-Grigoriou F, Stein H, Dörken B, Scheidereit C (2002) Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 21:4104–4113

    Article  PubMed  CAS  Google Scholar 

  27. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR (1992) AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89:9267–9271

    Article  PubMed  CAS  Google Scholar 

  28. Han EK, Begemann M, Sgambato A, Soh JW, Doki Y, Xing WQ, Liu W, Weinstein IB (1996) Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ 7:699–710

    PubMed  CAS  Google Scholar 

  29. Koga T, Iwasaki H, Ishiguro M, Matsuzaki A, Kikuchi M (2002) Losses in chromosomes 17, 19, and 22q in neurofibromatosis type 1 and sporadic neurofibromas: a comparative genomic hybridization analysis. Cancer Genet Cytogenet 136:113–120

    Article  PubMed  CAS  Google Scholar 

  30. Light JP, Roland JT Jr, Fishman A, Miller DC, Cohen NL (2001) Atypical and low-grade malignant vestibular schwannomas: clinical implications of proliferative activity. Otol Neurotol 22:922–927

    Article  PubMed  CAS  Google Scholar 

  31. Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN, Bates SE (1997) Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 89:1505–1515

    Article  PubMed  CAS  Google Scholar 

  32. Eccles SA (2001) The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 6:393–406

    Article  PubMed  CAS  Google Scholar 

  33. Clark JJ, Provenzano M, Diggelmann HR, Xu N, Hansen SS, Hansen MR (2008) The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otol Neurotol 29:846–853

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This study was supported by a grant of the foundation, Tumor Research Head and Neck, Wiesbaden, Germany.

Author information

Authors and Affiliations

  1. Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55101, Mainz, Germany

    Dimitrios Koutsimpelas, Uwe Felmeden, Wolf J. Mann & Jürgen Brieger

Authors
  1. Dimitrios Koutsimpelas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uwe Felmeden
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wolf J. Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jürgen Brieger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimitrios Koutsimpelas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koutsimpelas, D., Felmeden, U., Mann, W.J. et al. Analysis of cytogenetic aberrations in sporadic vestibular schwannoma by comparative genomic hybridization. J Neurooncol 103, 437–443 (2011). https://doi.org/10.1007/s11060-010-0412-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-010-0412-5

Keywords

Search

Navigation